Xu Qiu can completely choose other places, such as Daxia Pharmaceutical Corporation, where the other party’s R&D equipment, medical equipment, etc. are all top-notch, and the financial support that can be provided is also calculated in billions.

But he still chose to support pharmaceutical companies within Baiyun Province...

If Baiyun Pharmaceutical Factory is still thinking about the fixed assets in its hands, it would be too unkind.

Xu Qiu treated them sincerely, and the pharmaceutical factory had nothing to fear, so he just bet on everything!

"Sold it!" Many senior executives of Baiyun Pharmaceutical Factory breathed out and made up their minds.

...

At this time, Baiyun Pharmaceutical Factory's Drug Research and Development Institute.

Research teams at all levels are busy, and they have different emphasis. A total of seven top teams are conducting experiments and screening of different targets according to Xu Qiu's plan.

Drug development also has its basic steps before it moves to clinical trials.

The first thing is to find the target of drug action.

That is, the binding sites where drugs act in the body, including gene loci, receptor, enzyme, ion channel, and nucleic acid biological macromolecules.

After finding the target, the second thing is to find a compound that works on the target, also known as a lead compound.

Then, around the lead compound, a large number of new compounds are designed and synthesized, and the compounds with the best effect, best activity and least side effects are found.

Finally, select the candidate compound combination for formal development.

Only by completing these things can you start preclinical research and gradually move towards the clinical trial stage...

It's like aiming and shooting.

The target of action is the target that needs to be hit, and confirming the leading compound is to find the gunpowder to make the bullet; the subsequent compound arrangement and combination is to debug the ratio of the gunpowder to reach the maximum power; finally, the bullet will be further modified and improved, such as the bullet caliber, the bullet form, etc....

Now the R&D Institute is still at the point of drug targeting.

Even for ordinary tumors, there are not many targeted drugs, and the targeted drugs in liver cancer are extremely rare. The reason is that its heterogeneity is too strong, so it is very difficult to confirm the target.

Moreover, the liver cancer typing caused by different gene mutations is completely different, and the targets are naturally very different, which makes the research and development of targeted liver cancer drugs even more difficult.

Even the so-called magical drug sorafenib of liver cancer is not very universal, and only about 10 to 30% of patients can achieve results in clinical practice.

Xu Qiu chose liver cancer as his first drug development, which was the beginning of a nightmare difficulty.

"Effective molecular drug targets have at least three considerations...

"One is whether the target is significantly mutated in the tumor area, but is not expressed in the non-tumor area."

This is to make the drug more targeted and avoid damage to normal tissues.

This is also the magic of targeted drugs - they only kill cancer cells, but they cause less damage to other parts.

"The second point is the probability of the target expression."

For liver cancer, the best target is definitely expressed in all types of liver cancer, so that it can cover all liver cancers.

Of course, it is a fantasy to do this.

It is no exaggeration to say that if anyone can find a target that all liver cancers are expressed, he does not need to find a leading compound. Just this target will make global pharmaceutical giants rush to grab it. It is easy to buy hundreds of millions of berry dollars!

And it will inevitably leave a strong mark in medical history.

Although Xu Qiu has divine scientific research capabilities, it is almost impossible for him to do this within five months.

Liver cancer is the top cancer that plagues countless pharmaceutical companies. It is difficult to conquer one of the types of liver cancer alone. If you want to solve all types of liver cancer at one time, you will never dare to exaggerate it in your dreams.

Therefore, Xu Qiu first chose the type of hepatocellular liver cancer, which is also the most common liver cancer.

What the research and development is currently doing is to find targets expressed in hepatocellular liver cancer.

"The last aspect of the effective target is the characteristic of targeting!"

Even if a target is expressed in all hepatocellular carcinomas, it has nothing to do with the occurrence of cancer, and that's in vain.

At the same time, the target target must be required to be the main cause of cancer.

This is not over yet. Targets cause cancer is only one of the prerequisites. As a target for drug action, the tumor is inhibited after blocking it and will not occur again. It can be considered an effective target!

With the help of god-level scientific research capabilities, Xu Qiu screened 121 targets, which were expressed at high frequency in hepatocellular carcinoma, while seven R&D teams checked these targets one by one.

"Doctor Xu, the target CDK20 is very promising!" Han Chang, chief researcher of Team No. 1, said excitedly.

These days, they have been experimenting with the feasibility of CDK20.

After comparing 1,300 disease samples and 700 healthy controls, they found that CDK20 is closely related to the occurrence of hepatocellular carcinoma. As for whether the cancer will disappear after inhibiting CDK20, the results will be produced soon.

"Let's take a look." Xu Qiu asked for a stack of experimental materials and sat next to him and started reading.

Han Chang and others had long been accustomed to this scene and continued to study it on their own.

Many researchers gathered in front of a laboratory to test whether hepatocellular carcinoma after blocking CDK20 will be affected...

"The result is coming soon!" Han Chang was also extremely excited.

The precision instrument operated slowly, and an hour passed quickly.

But for researchers, this waiting is nothing.

Under the microscope, hepatocellular carcinoma slowly lost its activity, and everything that prompts hepatocellular carcinoma is decreasing rapidly...

"Success!" The laboratory burst into excited cheers.

Han Chang was so excited that he couldn't speak... CDK20 was really effective, and hepatocellular carcinoma was really dead after blocking it!

"Shh, quiet!" Suddenly, Han Chang noticed Xu Qiu, who was still flipping through the information. He pressed his palm and the laboratory returned to silence.

But the joy of the researchers could not be suppressed, and everyone gathered together and discussed in a low voice.

"It's done, it's done! I can't imagine it!"

"If it is a conventional drug development process, it will take half a year or even a year to find this target from countless molecules, but Dr. Xu directly provided us with 121 targets!"

"How did Dr. Xu think of it? Although the first few targets were excluded by us, they were all highly expressed in hepatocellular carcinoma. If you want to find these goals, even the world's largest pharmaceutical company can't do it, right?"

"How long did it take to find CDK20? It's less than a week? In three or four days, we found an available target. As long as we confirm its effectiveness, we can start testing the pilot compound. That is the official start of drug development!"

Everyone was very excited.

The eyes looked at Xu Qiu at the same time... They were all waiting, waiting for Xu Qiu to come back from his thoughts and tell him the good news.

After waiting for another two hours, Xu Qiu took back his gaze from the thick 100 pages of information.

Crash.

The voice of closing the information was particularly eye-catching in the quiet laboratory. Han Chang and others looked over at the same time, with their expressions revealing their impatience.
Chapter completed!